Krish Patel, MD, Swedish Cancer Institute, Seattle, WA, shares some insights into the management of cumulative side effects associated with BTK inhibitors in chronic lymphocytic leukemia (CLL), drawing focus on cardiovascular toxicities. This interview took place at the Eleventh Annual Meeting of the Society of Hematologic Oncology (SOHO 2023) held in Houston, TX.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.